Finding a Donor: HLA Matching and Haploidentical Transplant in Sickle Cell

Yes, this is done in practice. Since the minimum stem cell dose is 3 million cells per kilogram of the recipient's weight, a larger harvest can be divided into two doses for two patients. Where families want to proceed with one transplant first and the second once funds are arranged, half the dose is used immediately and the rest is cryopreserved for the second transplant later, sometimes with additional stimulating injections used to boost the donor's total yield.

No. Transplant replaces the blood-forming stem cell system, not the gene itself; the reproductive organs still carry the SS gene. The post-transplant patient will transmit one sickle gene to their offspring, and if their partner is also a carrier, their child can still be born with sickle cell disease. Families need to be counseled that both the patient and their partner should be tested once the child is grown and ready to have children of their own.

Transplant is safe from one year of age; the literature supports one year as the minimum, and the child's inability to verbally express discomfort is not the limiting factor, since transplants are routinely done for leukemia in infants as young as six to eight months when it is a do-or-die situation. What matters is that the body can tolerate the immunosuppression and the physical toll of the transplant, and that organs are sufficiently mature. One year is workable, but the preferred window remains two to five years, where outcomes are excellent.

Extreme environmental changes can occasionally trigger mild to moderate symptoms even in a carrier. High altitude without acclimatization, or cold temperatures causing vasoconstriction, can be enough to provoke symptoms from the 25 to 30% sickle hemoglobin a carrier naturally has, but these episodes are far less frequent and less severe than in a full sickle cell patient. Notably, this is the same threshold, 25 to 30% sickle hemoglobin, that explains why sickle cell transplant patients only need that much stable donor chimerism to stay symptom-free.

At day 30 the target is 95%, full donor chimerism. If it is falling, for example from 95% down to 70%, immunosuppressant drugs like cyclosporine or tacrolimus are reduced first and chimerism is rechecked after two weeks; if it recovers, reduced dosing continues. If it keeps falling, donor lymphocyte infusion follows, and a second transplant becomes necessary only if it drops below 5%. For the long term, the real target is stability rather than a fixed number, chimerism often settles at 50% or even 25 to 30% after some years, and if it holds there, the patient stays free of sickle symptoms, since sickle cell needs only 12 to 25% stable chimerism compared to the 80 to 85% required in thalassemia.

Any HLA match between 5 out of 10 and 9 out of 10 is considered haploidentical. Once the match clears 50%, whether it is 60%, 70%, or 90% makes no practical difference to the transplant outcome.

Yes. A full-match sibling who is an AS carrier can donate. The recipient converts to AS status after transplant and has no disease-related symptoms.